Founded in 2010, NeuroMax focuses on creating compounds with high efficacy and minimal side effects, making them competitive in the pharmaceutical market. Their drugs specifically target central and peripheral nervous system diseases, including diabetic neuropathy. With funding from Maxwell Biotech Venture Fund and support from Skolkovo Biomed Cluster, NeuroMax aims to revolutionize the treatment of these conditions. Their leading drug, NM-IA-001, has shown promising results in preclinical trials, demonstrating both high efficiency and a significant slowdown in the progression of diabetic neuropathy.